17,261 trials
Stage I Lung Non-Small Cell Cancer AJCC v7 · Stage IA Lung Non-Small Cell Carcinoma AJCC v7 · Stage IB Lung Non-Small Cell Carcinoma AJCC v7
Primary: Major Pathologic Response (mPR) — 5; 8; 7; 11 Participants
Schizophrenia
Primary: Cognitive Functions: Matrics Consensus Cognitive Battery (MCCB), Greek Verbal Test — 12.09; 19.04; 7.71; 14.00 score on a scale — p=.00
Type 1 Diabetes Mellitus
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAE) — 9; 6; 4; 1 participants
Ulcerative Colitis
Primary: Number of Treatment-emergent Adverse Events — 145 events
Alzheimer's Disease
Primary: 11C-PBR28 Binding — 1.25; 1.15; 1.16; 1.02 SUVR
AL Amyloidosis
Primary: Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) and Adverse Events (AEs), and AEs Leading to Treatment Discontinuation — 4; 3; 6; 13…
Atopic Dermatitis Eczema
Primary: Percent Change in Eczema Area and Severity Index (EASI) From Baseline to Week 8 — -43.5; -62.0 Percent change from baseline
Smoldering Multiple Myeloma
Primary: Proportion Of High Risk SMM Patients Who Are Progression Free 2 Years After Receiving IRD Combination Therapy — 50 Participants
Long COVID
Primary: Fatigue Severity Scale — -11.3; -8.6 score on a scale — p=0.46
Sensorineural Hearing Loss
Primary: Safety: Treatment-Emergent Adverse Events (TEAE) — 13; 5 Participants
Metastatic Colorectal Cancer · KRAS Gene Mutation
Primary: Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs) — 1; 1; 3 Participants
COVID-19 · Olfactory Disorder · Anosmia
Primary: Clinical Global Impression of Improvement Scale (CGI-I) — 8; 20; 7; 12 Participants
Gastrointestinal Stromal Tumors
Primary: Progression-Free Survival (PFS) — 6.44 months
Dry Eye
Primary: Change From Baseline in Subject-reported Ocular Dryness Score (0 - 100 Visual Analogue Scale (VAS)) — -16.0; -9.1 score on a scale
Non-small Cell Lung Cancer
Primary: Objective Response Rate (ORR) — 15.6 percentage of responders